Medical News and Perspectives
November 15, 2006

Researchers Probe Consequences of Androgen Deprivation for Prostate Cancer

JAMA. 2006;296(19):2305-2306. doi:10.1001/jama.296.19.2305

Boston—Because prostate cancer growth is fueled by androgens—especially testosterone—androgen deprivation therapy (ADT) is the treatment of choice for the 40% of men with this cancer who have disease that has spread beyond the prostate, a condition not amenable to surgical cure. While ADT achieves temporary symptom relief and tumor control in up to 80% of cases, this comes at a cost, said Laurence Katznelson, MD, associate professor of medicine and neurosurgery at Stanford University School of Medicine, Palo Alto, Calif.

First Page Preview View Large
First page PDF preview
First page PDF preview